Tillett is no fool. If you listen to the video release, he and Phil had been courting the replacement CSO for some months. I suspect the only thing that came as a shock was the board resignation.
I think it was largely driven by RAC "gaining a lot of international support really quickly" as noted by DCB in the video release yesterday. He also states "we have the opportunity to evolve the business, be able to commercialise the program".
The only way you commercialise a clinical program is by sacrificing IP. If that's under discussion now then they're doing it from too low a base. If Dominissini has indeed validated zan as an FTO inhibitor, that information should be released and marketed asap!
Ann: Race Leadership Changes, page-234
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.54 |
Change
-0.065(4.05%) |
Mkt cap ! $262.4M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.62 | $1.51 | $261.3K | 168.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2000 | 1 |
View Market Depth
| Last trade - 15.59pm 09/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |